TG Therapeutics, Inc. (0VGI.L)
USD 31.97
(-5.69%)
USD 31.97
(-5.69%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 198.47 Million USD | 1.6% |
| 2022 | 195.35 Million USD | -44.29% |
| 2021 | 350.66 Million USD | 28.1% |
| 2020 | 273.74 Million USD | 61.78% |
| 2019 | 169.2 Million USD | -3.06% |
| 2018 | 174.55 Million USD | 46.85% |
| 2017 | 118.86 Million USD | 50.23% |
| 2016 | 79.12 Million USD | 24.93% |
| 2015 | 63.33 Million USD | 13.35% |
| 2014 | 55.87 Million USD | 174.96% |
| 2013 | 20.32 Million USD | -21.27% |
| 2012 | 25.8 Million USD | 2826.33% |
| 2011 | 881.97 Thousand USD | -56.27% |
| 2010 | 2.01 Million USD | 13.84% |
| 2009 | 1.77 Million USD | -59.85% |
| 2008 | 4.41 Million USD | -63.66% |
| 2007 | 12.14 Million USD | 21.44% |
| 2006 | 10 Million USD | -48.34% |
| 2005 | 19.35 Million USD | 215.12% |
| 2004 | 6.14 Million USD | 29.1% |
| 2003 | 4.75 Million USD | 131.79% |
| 2002 | 2.05 Million USD | -45.06% |
| 2001 | 3.73 Million USD | -16.26% |
| 2000 | 4.46 Million USD | 43.94% |
| 1999 | 3.1 Million USD | -47.46% |
| 1998 | 5.9 Million USD | 7.27% |
| 1997 | 5.5 Million USD | 41.03% |
| 1996 | 3.9 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 67.22 Million USD | 38.57% |
| 2024 Q2 | 56.27 Million USD | -16.29% |
| 2024 Q3 | 62.1 Million USD | 10.36% |
| 2023 Q2 | 58.83 Million USD | 33.91% |
| 2023 Q4 | 48.51 Million USD | 2.08% |
| 2023 Q1 | 43.93 Million USD | -15.73% |
| 2023 FY | 198.47 Million USD | 1.6% |
| 2023 Q3 | 47.52 Million USD | -19.23% |
| 2022 Q3 | 35.05 Million USD | -11.28% |
| 2022 Q4 | 52.13 Million USD | 48.73% |
| 2022 Q2 | 39.51 Million USD | -42.45% |
| 2022 FY | 195.35 Million USD | -44.29% |
| 2022 Q1 | 68.65 Million USD | -27.78% |
| 2021 Q1 | 89.85 Million USD | 3.5% |
| 2021 FY | 350.66 Million USD | 28.1% |
| 2021 Q2 | 78.88 Million USD | -12.21% |
| 2021 Q3 | 86.86 Million USD | 10.11% |
| 2021 Q4 | 95.05 Million USD | 9.43% |
| 2020 Q4 | 86.81 Million USD | 1.23% |
| 2020 Q3 | 85.76 Million USD | 68.54% |
| 2020 Q1 | 50.28 Million USD | 32.33% |
| 2020 FY | 273.74 Million USD | 61.78% |
| 2020 Q2 | 50.88 Million USD | 1.19% |
| 2019 FY | 169.2 Million USD | -3.06% |
| 2019 Q4 | 37.99 Million USD | -37.6% |
| 2019 Q1 | 34.72 Million USD | -35.91% |
| 2019 Q2 | 35.58 Million USD | 2.46% |
| 2019 Q3 | 60.89 Million USD | 71.15% |
| 2018 Q3 | 34.36 Million USD | -22.57% |
| 2018 Q4 | 54.18 Million USD | 57.68% |
| 2018 FY | 174.55 Million USD | 46.85% |
| 2018 Q1 | 41.61 Million USD | 33.93% |
| 2018 Q2 | 44.38 Million USD | 6.65% |
| 2017 Q3 | 31.62 Million USD | 11.1% |
| 2017 FY | 118.86 Million USD | 50.23% |
| 2017 Q4 | 31.07 Million USD | -1.74% |
| 2017 Q1 | 27.7 Million USD | 15.12% |
| 2017 Q2 | 28.46 Million USD | 2.74% |
| 2016 FY | 79.12 Million USD | 24.93% |
| 2016 Q1 | 14.03 Million USD | -20.63% |
| 2016 Q2 | 16.06 Million USD | 14.48% |
| 2016 Q3 | 24.96 Million USD | 55.42% |
| 2016 Q4 | 24.06 Million USD | -3.59% |
| 2015 Q4 | 17.67 Million USD | 27.51% |
| 2015 Q1 | 14.64 Million USD | -21.95% |
| 2015 Q2 | 17.14 Million USD | 17.14% |
| 2015 Q3 | 13.86 Million USD | -19.16% |
| 2015 FY | 63.33 Million USD | 13.35% |
| 2014 Q4 | 18.75 Million USD | 7.33% |
| 2014 FY | 55.87 Million USD | 174.96% |
| 2014 Q3 | 17.47 Million USD | 45.72% |
| 2014 Q2 | 11.99 Million USD | 56.92% |
| 2014 Q1 | 7.64 Million USD | 46.53% |
| 2013 Q2 | 6.66 Million USD | 77.68% |
| 2013 Q1 | 3.75 Million USD | 44.04% |
| 2013 FY | 20.32 Million USD | -21.27% |
| 2013 Q4 | 5.21 Million USD | 11.33% |
| 2013 Q3 | 4.68 Million USD | -29.72% |
| 2012 Q3 | 2.71 Million USD | -12.58% |
| 2012 Q4 | 2.6 Million USD | -4.03% |
| 2012 FY | 25.8 Million USD | 2826.33% |
| 2012 Q1 | 17.38 Million USD | 6566.32% |
| 2012 Q2 | 3.1 Million USD | -82.14% |
| 2011 Q2 | 322.9 Thousand USD | -42.96% |
| 2011 Q3 | 261.84 Thousand USD | -18.91% |
| 2011 FY | 881.97 Thousand USD | -56.27% |
| 2011 Q4 | -268.86 Thousand USD | -202.68% |
| 2011 Q1 | 566.08 Thousand USD | 26.76% |
| 2010 Q1 | 529.44 Thousand USD | 55.12% |
| 2010 Q2 | 525.09 Thousand USD | -0.82% |
| 2010 Q3 | 515.63 Thousand USD | -1.8% |
| 2010 FY | 2.01 Million USD | 13.84% |
| 2010 Q4 | 446.56 Thousand USD | -13.39% |
| 2009 Q2 | 477.26 Thousand USD | -14.37% |
| 2009 Q3 | 395.64 Thousand USD | -17.1% |
| 2009 FY | 1.77 Million USD | -59.85% |
| 2009 Q4 | 341.32 Thousand USD | -13.73% |
| 2009 Q1 | 557.33 Thousand USD | 1166.61% |
| 2008 Q3 | 1.38 Million USD | -5.71% |
| 2008 Q4 | -52.25 Thousand USD | -103.78% |
| 2008 FY | 4.41 Million USD | -63.66% |
| 2008 Q1 | 1.61 Million USD | -15.88% |
| 2008 Q2 | 1.46 Million USD | -9.1% |
| 2007 Q1 | 2.59 Million USD | -18.43% |
| 2007 Q4 | 1.91 Million USD | -29.12% |
| 2007 Q3 | 2.7 Million USD | -45.02% |
| 2007 Q2 | 4.92 Million USD | 89.81% |
| 2007 FY | 12.14 Million USD | 21.44% |
| 2006 Q1 | 2.91 Million USD | -79.94% |
| 2006 Q2 | 2.35 Million USD | -19.11% |
| 2006 Q4 | 3.18 Million USD | 61.81% |
| 2006 Q3 | 1.96 Million USD | -16.62% |
| 2006 FY | 10 Million USD | -48.34% |
| 2005 Q4 | 14.52 Million USD | 680.38% |
| 2005 Q2 | 1.51 Million USD | 3.64% |
| 2005 FY | 19.35 Million USD | 215.12% |
| 2005 Q1 | 1.45 Million USD | -18.67% |
| 2005 Q3 | 1.86 Million USD | 23.25% |
| 2004 Q3 | 2.24 Million USD | 127.19% |
| 2004 Q1 | 1.12 Million USD | -26.17% |
| 2004 Q4 | 1.79 Million USD | -20.06% |
| 2004 FY | 6.14 Million USD | 29.1% |
| 2004 Q2 | 986.71 Thousand USD | -12.1% |
| 2003 FY | 4.75 Million USD | 131.79% |
| 2003 Q1 | 422.22 Thousand USD | 15.23% |
| 2003 Q2 | 777.02 Thousand USD | 84.03% |
| 2003 Q3 | 2.03 Million USD | 162.38% |
| 2003 Q4 | 1.52 Million USD | -25.43% |
| 2002 Q1 | 629.59 Thousand USD | 12.79% |
| 2002 Q3 | 588.24 Thousand USD | 25.51% |
| 2002 FY | 2.05 Million USD | -45.06% |
| 2002 Q4 | 366.4 Thousand USD | -37.71% |
| 2002 Q2 | 468.67 Thousand USD | -25.56% |
| 2001 Q4 | 558.19 Thousand USD | -20.77% |
| 2001 FY | 3.73 Million USD | -16.26% |
| 2001 Q1 | 880.68 Thousand USD | 149.87% |
| 2001 Q2 | 1.17 Million USD | 33.76% |
| 2001 Q3 | 704.51 Thousand USD | -40.19% |
| 2000 Q3 | 1.19 Million USD | -64.82% |
| 2000 Q1 | 1.62 Million USD | 103.71% |
| 2000 FY | 4.46 Million USD | 43.94% |
| 2000 Q2 | 3.4 Million USD | 108.73% |
| 2000 Q4 | -1.76 Million USD | -247.57% |
| 1999 FY | 3.1 Million USD | -47.46% |
| 1999 Q4 | 800 Thousand USD | 33.33% |
| 1999 Q3 | 600 Thousand USD | -14.29% |
| 1999 Q2 | 700 Thousand USD | -30.0% |
| 1999 Q1 | 1 Million USD | -33.33% |
| 1998 FY | 5.9 Million USD | 7.27% |
| 1998 Q2 | 1.7 Million USD | 21.43% |
| 1998 Q3 | 1.3 Million USD | -23.53% |
| 1998 Q4 | 1.5 Million USD | 15.38% |
| 1998 Q1 | 1.4 Million USD | -17.65% |
| 1997 Q3 | 1.1 Million USD | -38.89% |
| 1997 Q4 | 1.7 Million USD | 54.55% |
| 1997 FY | 5.5 Million USD | 41.03% |
| 1997 Q1 | 900 Thousand USD | -25.0% |
| 1997 Q2 | 1.8 Million USD | 100.0% |
| 1996 Q3 | 1.2 Million USD | 71.43% |
| 1996 Q4 | 1.2 Million USD | 0.0% |
| 1996 FY | 3.9 Million USD | 0.0% |
| 1996 Q1 | - USD | 0.0% |
| 1996 Q2 | 700 Thousand USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Thermo Fisher Scientific Inc. | 10.25 Billion USD | 98.064% |
| Dynavax Technologies Corporation | 219.14 Million USD | 9.432% |
| Illumina, Inc. | 3.81 Billion USD | 94.795% |
| IQVIA Holdings Inc. | 2.05 Billion USD | 90.332% |
| Biogen Inc. | 5.2 Billion USD | 96.187% |
| Iovance Biotherapeutics, Inc. | 450.99 Million USD | 55.992% |
| Mettler-Toledo International Inc. | 1.08 Billion USD | 81.781% |
| Sarepta Therapeutics, Inc. | 1.36 Billion USD | 85.415% |
| Supernus Pharmaceuticals, Inc. | 529.01 Million USD | 62.482% |
| Waters Corporation | 943.51 Million USD | 78.964% |
| Perrigo Company plc | 1.52 Billion USD | 87.015% |
| uniQure N.V. | 285.08 Million USD | 30.381% |
| Agios Pharmaceuticals, Inc. | 408.8 Million USD | 51.45% |
| Amicus Therapeutics, Inc. | 427.65 Million USD | 53.589% |
| Atara Biotherapeutics, Inc. | 275.69 Million USD | 28.009% |
| bluebird bio, Inc. | 240.23 Million USD | 17.382% |
| Cara Therapeutics, Inc. | 142.46 Million USD | -39.317% |
| Imunon, Inc. | 21.03 Million USD | -843.752% |
| Myriad Genetics, Inc. | 600.1 Million USD | 66.926% |
| Neurocrine Biosciences, Inc. | 1.59 Billion USD | 87.568% |
| Nektar Therapeutics | 190.9 Million USD | -3.966% |
| Editas Medicine, Inc. | 247.3 Million USD | 19.745% |
| Verastem, Inc. | 92.08 Million USD | -115.537% |
| Walgreens Boots Alliance, Inc. | 40.6 Billion USD | 99.511% |
| Corbus Pharmaceuticals Holdings, Inc. | 13.9 Million USD | -1326.888% |
| Heron Therapeutics, Inc. | 120.65 Million USD | -64.495% |
| Unity Biotechnology, Inc. | 44.66 Million USD | -344.344% |
| BioMarin Pharmaceutical Inc. | 1.74 Billion USD | 88.634% |
| Sangamo Therapeutics, Inc. | 228.68 Million USD | 13.208% |
| Evolus, Inc. | 189.75 Million USD | -4.593% |
| Adicet Bio, Inc. | 152.03 Million USD | -30.543% |
| Aclaris Therapeutics, Inc. | 12.14 Million USD | -1534.75% |
| Regeneron Pharmaceuticals, Inc. | 2.81 Billion USD | 92.95% |
| Esperion Therapeutics, Inc. | 271.89 Million USD | 27.004% |
| FibroGen, Inc. | 398.11 Million USD | 50.146% |
| Agilent Technologies, Inc. | 2.11 Billion USD | 90.616% |
| OPKO Health, Inc. | 574.68 Million USD | 65.464% |
| Homology Medicines, Inc. | 9.87 Million USD | -1909.873% |
| Geron Corporation | 70.44 Million USD | -181.761% |
| Alnylam Pharmaceuticals, Inc. | 1.8 Billion USD | 88.974% |
| Exelixis, Inc. | 1.58 Billion USD | 87.492% |
| Viking Therapeutics, Inc. | 100.82 Million USD | -96.847% |
| Anavex Life Sciences Corp. | 55.75 Million USD | -255.971% |
| Intellia Therapeutics, Inc. | 551.56 Million USD | 64.016% |
| Zoetis Inc. | 2.76 Billion USD | 92.822% |
| Axsome Therapeutics, Inc. | 476.36 Million USD | 58.335% |
| Abeona Therapeutics Inc. | 48.5 Million USD | -309.21% |
| Vertex Pharmaceuticals Incorporated | 4.77 Billion USD | 95.843% |
| Kala Pharmaceuticals, Inc. | 39.15 Million USD | -406.922% |
| Ionis Pharmaceuticals, Inc. | 779.58 Million USD | 74.541% |
| Corcept Therapeutics Incorporated | 368.61 Million USD | 46.156% |
| Halozyme Therapeutics, Inc. | 299.31 Million USD | 33.691% |
| Blueprint Medicines Corporation | 722.86 Million USD | 72.543% |
| Insmed Incorporated | 949.26 Million USD | 79.092% |
| Incyte Corporation | 1.19 Billion USD | 83.328% |
| Emergent BioSolutions Inc. | 1.04 Billion USD | 80.989% |